Siolta Therapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
930 Brittan Ave, San Carlos, California,...Phone Number
(415) 991-0947Website
www.sioltatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Siolta Therapeutics
Siolta Therapeutics was founded in 2016 by Susan Lynch, PhD (University of California at San Francisco, UCSF) and Nikole Kimes, PhD (Siolta, formerly UCSF) in partnership with Samir Kaul (Khosla Ventures). Siolta is a biotech company on a mission to alleviate the suffering of those impacted by chronic inflammatory diseases through novel microbiome-based medicines. Siolta leverages their deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. The company's blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform that represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.Explore more
Siolta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Siolta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Siolta Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Siolta Therapeutics launches new products
Check if Siolta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Siolta Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Siolta Therapeutics
Check out if Siolta Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Siolta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Siolta Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Siolta Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Siolta Therapeutics
Compare insights from companies similar to Siolta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Siolta Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Siolta Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Siolta Therapeutics.
Siolta Therapeutics financials insights
Gather financial insights about Siolta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series C
$12M
Siolta Therapeutics Tech Stack
A closer look at the technologies used by Siolta Therapeutics
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Funding
Project
received an award of $300,000 on August 14, 2023 by HHS NIH with an award end date of July 31, 2024.
Award, Spending/Investment
Funding
Funding
Siolta Therapeutics News & Media
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
STMC-103H exhibited 64% reduction in the risk of atopic dermatitis in subjects who completed one year of treatment with strong and consistent effects across multiple efficacy endpoints and was safe and well-tolerated SAN CARLOS, Calif., Nov. 17, 2025 /PRNewswire/ -- Siolta Therapeutics, a...Siolta Therapeutics and Cowellnex Enter Joint Research Agreement
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #livebiotherapeuticproducts--Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), and Cowellnex Co. Ltd, a Kirin and Kyowa Kirin joint investment, have signed a preclinical joint research agreement to develop an LBP aimed at the prevention of necrotizing enterocolitis (NEC). This collaboration combines Siolta’s expertise in microbial science with Cowellnex’s institutional strength to advance research and establish treatmenNexilico and Siolta Therapeutics Enter Collaboration Agreement to Develop a Novel Microbiome Therapeutic for Necrotizing Enterocolitis
DANVILLE, Calif.--(BUSINESS WIRE)-- #AI--Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), have entered into a collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics. This partnership combines Nexilico's modality-agnostic AI-driven discovery platform with Siolta’s expertise in developing targeted biotherapeutics, setting the stage for innovativeSiolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #livebiotherapeuticproducts--Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics. The funds raised in this round will support the further clinical development of Siolta’s lead product, STMC-103H, a
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Siolta Therapeutics
Sign Up For FreeTo access detailed company insights
Siolta Therapeutics was founded in 2016 by Susan Lynch, PhD (University of California at San Francisco, UCSF) and Nikole Kimes, PhD (Siolta, formerly UCSF) in partnership with Samir Kaul (Khosla Ventures). Siolta is a biotech company on a mission to alleviate the suffering of those impacted by chronic inflammatory diseases through novel microbiome-... Read More
